{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Myeloid+Leukemia%2FAcute+Lymphoblastic+Leukemia&page=10",
    "query": {
      "condition": "Acute Myeloid Leukemia/Acute Lymphoblastic Leukemia",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 935,
    "total_pages": 94,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Myeloid+Leukemia%2FAcute+Lymphoblastic+Leukemia&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Acute+Myeloid+Leukemia%2FAcute+Lymphoblastic+Leukemia&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-13T21:53:33.495Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02793544",
      "title": "HLA-Mismatched Unrelated Donor Bone Marrow Transplantation With Post-Transplantation Cyclophosphamide",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome (MDS)",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Chemotherapy-sensitive Lymphoma",
        "Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma",
        "Acute Myelogenous Leukemia (AML)",
        "Acute Biphenotypic Leukemia (ABL)",
        "Acute Undifferentiated Leukemia (AUL)"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation (TBI) 200cGy on Day -1",
          "type": "RADIATION"
        },
        {
          "name": "Infusion of non-T-cell depleted bone marrow on Day 0",
          "type": "PROCEDURE"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 50mg/kg/day IV on Days -2,-1",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide 50mg/kg/day IV on Days -5,-4",
          "type": "DRUG"
        },
        {
          "name": "Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1",
          "type": "RADIATION"
        },
        {
          "name": "Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "Mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Pre-HCT Mesna on Days -6 and -5",
          "type": "DRUG"
        },
        {
          "name": "Pre-HCT Mesna on Days -2 and -1",
          "type": "DRUG"
        },
        {
          "name": "Pre-HCT Mesna on Days -5 and -4",
          "type": "DRUG"
        },
        {
          "name": "Post-HCT Mesna",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Center for International Blood and Marrow Transplant Research",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "15 Years to 70 Years"
      },
      "enrollment_count": 80,
      "start_date": "2016-12",
      "completion_date": "2020-03",
      "has_results": true,
      "last_update_posted_date": "2025-08-06",
      "last_synced_at": "2026-10-13T21:53:33.495Z",
      "location_count": 11,
      "location_summary": "Gainesville, Florida • Miami, Florida • Tampa, Florida + 7 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02793544"
    },
    {
      "nct_id": "NCT05107856",
      "title": "PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "B-cell Non-Hodgkin Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Chronic Myelomonocytic Leukemia",
        "Follicular Lymphoma",
        "Mantle Cell Lymphoma",
        "Marginal Zone Lymphoma",
        "Myelodysplastic Syndromes",
        "Myeloproliferative Neoplasm",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "PRT1419",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Prelude Therapeutics Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2022-03-22",
      "completion_date": "2024-01-19",
      "has_results": false,
      "last_update_posted_date": "2024-01-31",
      "last_synced_at": "2026-10-13T21:53:33.495Z",
      "location_count": 9,
      "location_summary": "Orange City, Florida • Orlando, Florida • Bethesda, Maryland + 6 more",
      "locations": [
        {
          "city": "Orange City",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        },
        {
          "city": "Brick",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05107856"
    },
    {
      "nct_id": "NCT00217412",
      "title": "Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Childhood Acute Promyelocytic Leukemia (M3)",
        "Childhood Atypical Teratoid/Rhabdoid Tumor",
        "Childhood Burkitt Lymphoma",
        "Childhood Chronic Myelogenous Leukemia",
        "Childhood Diffuse Large Cell Lymphoma",
        "Childhood Immunoblastic Large Cell Lymphoma",
        "Juvenile Myelomonocytic Leukemia",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia",
        "Recurrent Childhood Grade III Lymphomatoid Granulomatosis",
        "Recurrent Childhood Large Cell Lymphoma",
        "Recurrent Childhood Lymphoblastic Lymphoma",
        "Recurrent Childhood Medulloblastoma",
        "Recurrent Childhood Small Noncleaved Cell Lymphoma",
        "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor",
        "Recurrent Neuroblastoma",
        "Recurrent/Refractory Childhood Hodgkin Lymphoma",
        "Relapsing Chronic Myelogenous Leukemia",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "vorinostat",
          "type": "DRUG"
        },
        {
          "name": "isotretinoin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 60,
      "start_date": "2005-08",
      "completion_date": "2009-09",
      "has_results": false,
      "last_update_posted_date": "2014-06-17",
      "last_synced_at": "2026-10-13T21:53:33.495Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00217412"
    },
    {
      "nct_id": "NCT00911066",
      "title": "MLN4924 for the Treatment of Acute Myelogenous Leukemia, Myelodysplastic Syndrome, and Acute Lymphoblastic Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myelogenous Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "MLN4924",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2009-06",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2013-12-05",
      "last_synced_at": "2026-10-13T21:53:33.495Z",
      "location_count": 6,
      "location_summary": "Stanford, California • Chicago, Illinois • Baltimore, Maryland + 3 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00911066"
    },
    {
      "nct_id": "NCT02094794",
      "title": "Total Marrow and Lymphoid Irradiation and Chemotherapy Before DSCT in Treating Patients With High-Risk ALL or AML",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Del(5q)",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Childhood Acute Lymphoblastic Leukemia",
        "Recurrent Childhood Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "total marrow irradiation",
          "type": "RADIATION"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "16 Years to 60 Years"
      },
      "enrollment_count": 108,
      "start_date": "2014-05-12",
      "completion_date": "2027-05-04",
      "has_results": false,
      "last_update_posted_date": "2026-07-01",
      "last_synced_at": "2026-10-13T21:53:33.495Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02094794"
    },
    {
      "nct_id": "NCT01572662",
      "title": "Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia",
        "Acute Myeloid Leukemia",
        "Acute Lymphocytic Leukemia",
        "Chronic Myeloid Leukemia",
        "Chronic Lymphocytic Leukemia",
        "Myeloproliferative Diseases",
        "Non-Hodgkins Lymphoma",
        "Hodgkins Lymphoma",
        "Multiple Myeloma",
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "Fludarabine monophosphate",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Stem Cell Infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "Tacrolimus",
          "type": "DRUG"
        },
        {
          "name": "Methotrexate",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "5 Years to 75 Years"
      },
      "enrollment_count": 201,
      "start_date": "2012-04-11",
      "completion_date": "2022-08-11",
      "has_results": true,
      "last_update_posted_date": "2023-06-29",
      "last_synced_at": "2026-10-13T21:53:33.495Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01572662"
    },
    {
      "nct_id": "NCT01076270",
      "title": "Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Accelerated Phase Chronic Myelogenous Leukemia",
        "Adult Acute Lymphoblastic Leukemia in Remission",
        "Adult Acute Myeloid Leukemia in Remission",
        "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities",
        "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)",
        "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)",
        "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)",
        "Atypical Chronic Myeloid Leukemia, BCR-ABL Negative",
        "Blastic Phase Chronic Myelogenous Leukemia",
        "Chronic Phase Chronic Myelogenous Leukemia",
        "de Novo Myelodysplastic Syndromes",
        "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue",
        "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable",
        "Nodal Marginal Zone B-cell Lymphoma",
        "Noncontiguous Stage II Adult Burkitt Lymphoma",
        "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma",
        "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma",
        "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma",
        "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma",
        "Noncontiguous Stage II Adult Lymphoblastic Lymphoma",
        "Noncontiguous Stage II Grade 1 Follicular Lymphoma",
        "Noncontiguous Stage II Grade 2 Follicular Lymphoma",
        "Noncontiguous Stage II Grade 3 Follicular Lymphoma",
        "Noncontiguous Stage II Mantle Cell Lymphoma",
        "Noncontiguous Stage II Marginal Zone Lymphoma",
        "Noncontiguous Stage II Small Lymphocytic Lymphoma",
        "Previously Treated Myelodysplastic Syndromes",
        "Recurrent Adult Acute Lymphoblastic Leukemia",
        "Recurrent Adult Acute Myeloid Leukemia",
        "Recurrent Adult Burkitt Lymphoma",
        "Recurrent Adult Diffuse Large Cell Lymphoma",
        "Recurrent Adult Diffuse Mixed Cell Lymphoma",
        "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma",
        "Recurrent Adult Hodgkin Lymphoma",
        "Recurrent Adult Immunoblastic Large Cell Lymphoma",
        "Recurrent Adult Lymphoblastic Lymphoma",
        "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Mantle Cell Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Mycosis Fungoides/Sezary Syndrome",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Hairy Cell Leukemia",
        "Refractory Multiple Myeloma",
        "Relapsing Chronic Myelogenous Leukemia",
        "Secondary Acute Myeloid Leukemia",
        "Secondary Myelodysplastic Syndromes",
        "Splenic Marginal Zone Lymphoma",
        "Stage I Multiple Myeloma",
        "Stage II Multiple Myeloma",
        "Stage III Adult Burkitt Lymphoma",
        "Stage III Adult Diffuse Large Cell Lymphoma",
        "Stage III Adult Diffuse Mixed Cell Lymphoma",
        "Stage III Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage III Adult Hodgkin Lymphoma",
        "Stage III Adult Immunoblastic Large Cell Lymphoma",
        "Stage III Adult Lymphoblastic Lymphoma",
        "Stage III Chronic Lymphocytic Leukemia",
        "Stage III Grade 1 Follicular Lymphoma",
        "Stage III Grade 2 Follicular Lymphoma",
        "Stage III Grade 3 Follicular Lymphoma",
        "Stage III Mantle Cell Lymphoma",
        "Stage III Marginal Zone Lymphoma",
        "Stage III Multiple Myeloma",
        "Stage III Small Lymphocytic Lymphoma",
        "Stage IV Adult Burkitt Lymphoma",
        "Stage IV Adult Diffuse Large Cell Lymphoma",
        "Stage IV Adult Diffuse Mixed Cell Lymphoma",
        "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma",
        "Stage IV Adult Hodgkin Lymphoma",
        "Stage IV Adult Immunoblastic Large Cell Lymphoma",
        "Stage IV Adult Lymphoblastic Lymphoma",
        "Stage IV Chronic Lymphocytic Leukemia",
        "Stage IV Grade 1 Follicular Lymphoma",
        "Stage IV Grade 2 Follicular Lymphoma",
        "Stage IV Grade 3 Follicular Lymphoma",
        "Stage IV Mantle Cell Lymphoma",
        "Stage IV Marginal Zone Lymphoma",
        "Stage IV Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "plerixafor",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 1,
      "start_date": "2010-06",
      "completion_date": "2011-02",
      "has_results": true,
      "last_update_posted_date": "2017-06-28",
      "last_synced_at": "2026-10-13T21:53:33.495Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01076270"
    },
    {
      "nct_id": "NCT00083070",
      "title": "Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 16,
      "start_date": "2004-03",
      "completion_date": "2008-06",
      "has_results": false,
      "last_update_posted_date": "2014-02-20",
      "last_synced_at": "2026-10-13T21:53:33.495Z",
      "location_count": 14,
      "location_summary": "Stanford, California • Indianapolis, Indiana • Minneapolis, Minnesota + 11 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00083070"
    },
    {
      "nct_id": "NCT00167180",
      "title": "Post Transplant Donor Lymphocyte Infusion",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia, Myeloid, Chronic",
        "Lymphomas",
        "Multiple Myeloma",
        "Myelodysplastic Syndrome",
        "Leukemia, Lymphocytic, Acute",
        "Leukemia, Lymphocytic, Chronic",
        "AML"
      ],
      "interventions": [
        {
          "name": "Donor Lymphocyte Infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "Induction Chemotherapy",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "1 Year to 70 Years"
      },
      "enrollment_count": 57,
      "start_date": "2004-01",
      "completion_date": "2018-12-24",
      "has_results": true,
      "last_update_posted_date": "2019-07-30",
      "last_synced_at": "2026-10-13T21:53:33.495Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00167180"
    },
    {
      "nct_id": "NCT01139151",
      "title": "4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "3 Day Thiarabine",
          "type": "DRUG"
        },
        {
          "name": "5 Day Thiarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2010-08",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2014-06-17",
      "last_synced_at": "2026-10-13T21:53:33.495Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01139151"
    }
  ]
}